AR125041A1 - Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix, y su uso - Google Patents
Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix, y su usoInfo
- Publication number
- AR125041A1 AR125041A1 ARP220100514A ARP220100514A AR125041A1 AR 125041 A1 AR125041 A1 AR 125041A1 AR P220100514 A ARP220100514 A AR P220100514A AR P220100514 A ARP220100514 A AR P220100514A AR 125041 A1 AR125041 A1 AR 125041A1
- Authority
- AR
- Argentina
- Prior art keywords
- codon
- nucleic acid
- seq
- gene
- expression cassette
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 title abstract 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 title abstract 3
- 239000003114 blood coagulation factor Substances 0.000 title abstract 3
- 229960004222 factor ix Drugs 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 2
- 208000009429 hemophilia B Diseases 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000008488 polyadenylation Effects 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 108010071690 Prealbumin Proteins 0.000 abstract 1
- 102000009190 Transthyretin Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente solicitud está relacionada con los campos de la genética, la terapia génica y la biología molecular. Más específicamente, la presente invención se refiere a un ácido nucleico aislado optimizado en codones que codifica la proteína FIX (factor de coagulación IX), un casete de expresión y un vector basado en el mismo, así como un virus recombinante basado en el AAV5 (virus adenoasociado de serotipo 5) para aumentar la expresión del gen FIX en las células diana, y su uso. Reivindicación 1: Un ácido nucleico aislado optimizado en codones que codifica la proteína FIX (factor de coagulación IX) que tiene la secuencia de aminoácidos de SEQ ID Nº 1, que incluye una secuencia de nucleótidos que se selecciona del grupo que comprende: SEQ ID Nº 2 o SEQ ID Nº 4. Reivindicación 2: Un casete de expresión que incluye el ácido nucleico optimizado para el codón según la reivindicación 1. Reivindicación 3: El casete de expresión según la reivindicación 2, que comprende los siguientes elementos en la dirección del extremo 5 al extremo 3: una ITR (repeticiones terminales invertidas) izquierda (primera); Promotor de la TTR (promotor de la transtiretina); un intrón del gen hBG1 (un fragmento con intrón del gen de la b-globina humana); el ácido nucleico optimizado por codones según la reivindicación 1; una señal de poliadenilación hGH1 (señal de poliadenilación del gen de la hormona de crecimiento humana); una ITR derecha (segunda). Reivindicación 4: El casete de expresión como se reivindica en la reivindicación 3, que incluye una secuencia de nucleótidos que se selecciona del grupo que comprende: SEQ ID Nº 3 o SEQ ID Nº 5. Reivindicación 6: Un virus recombinante aislado basado en el AAV5 (virus adenoasociado de serotipo 5) para aumentar la expresión del gen FIX en las células diana, que incluye el ácido nucleico optimizado para el codón según la reivindicación 1 o el casete de expresión según cualquiera de las reivindicaciones 2 a 4. Reivindicación 20: Un método para tratar la hemofilia B en un sujeto, que comprende la administración de una cantidad terapéuticamente eficaz del virus recombinante basado en AAV5 como se reivindica en cualquiera de las reivindicaciones 6 a 13 o la composición como se reivindica en la reivindicación 14 en un sujeto que tiene hemofilia B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021105703A RU2021105703A (ru) | 2021-03-05 | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125041A1 true AR125041A1 (es) | 2023-05-31 |
Family
ID=83154378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100514A AR125041A1 (es) | 2021-03-05 | 2022-03-07 | Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix, y su uso |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240076691A1 (es) |
| EP (1) | EP4288549A1 (es) |
| JP (1) | JP2024509224A (es) |
| KR (1) | KR20230154067A (es) |
| CN (1) | CN117716038A (es) |
| AR (1) | AR125041A1 (es) |
| AU (1) | AU2022230548A1 (es) |
| BR (1) | BR112023018003A2 (es) |
| CA (1) | CA3212809A1 (es) |
| CL (1) | CL2023002629A1 (es) |
| CO (1) | CO2023011679A2 (es) |
| CR (1) | CR20230429A (es) |
| EC (1) | ECSP23067213A (es) |
| IL (1) | IL305679A (es) |
| MA (1) | MA62371A1 (es) |
| MX (1) | MX2023010350A (es) |
| TW (1) | TW202246505A (es) |
| UY (1) | UY39659A (es) |
| WO (1) | WO2022186734A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| US10842853B2 (en) * | 2017-05-22 | 2020-11-24 | Baxalta Incorporated | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B |
-
2022
- 2022-03-04 TW TW111108106A patent/TW202246505A/zh unknown
- 2022-03-05 CR CR20230429A patent/CR20230429A/es unknown
- 2022-03-05 MX MX2023010350A patent/MX2023010350A/es unknown
- 2022-03-05 WO PCT/RU2022/050073 patent/WO2022186734A1/en active Application Filing
- 2022-03-05 IL IL305679A patent/IL305679A/en unknown
- 2022-03-05 BR BR112023018003A patent/BR112023018003A2/pt unknown
- 2022-03-05 AU AU2022230548A patent/AU2022230548A1/en active Pending
- 2022-03-05 JP JP2023554061A patent/JP2024509224A/ja active Pending
- 2022-03-05 EP EP22763678.4A patent/EP4288549A1/en active Pending
- 2022-03-05 KR KR1020237034078A patent/KR20230154067A/ko unknown
- 2022-03-05 CN CN202280017566.8A patent/CN117716038A/zh active Pending
- 2022-03-05 MA MA62371A patent/MA62371A1/fr unknown
- 2022-03-05 US US18/280,338 patent/US20240076691A1/en active Pending
- 2022-03-05 CA CA3212809A patent/CA3212809A1/en active Pending
- 2022-03-07 UY UY0001039659A patent/UY39659A/es unknown
- 2022-03-07 AR ARP220100514A patent/AR125041A1/es unknown
-
2023
- 2023-09-04 CO CONC2023/0011679A patent/CO2023011679A2/es unknown
- 2023-09-04 CL CL2023002629A patent/CL2023002629A1/es unknown
- 2023-09-05 EC ECSENADI202367213A patent/ECSP23067213A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202246505A (zh) | 2022-12-01 |
| WO2022186734A1 (en) | 2022-09-09 |
| MA62371A1 (fr) | 2024-03-29 |
| ECSP23067213A (es) | 2023-10-31 |
| BR112023018003A2 (pt) | 2023-12-26 |
| KR20230154067A (ko) | 2023-11-07 |
| EP4288549A1 (en) | 2023-12-13 |
| MX2023010350A (es) | 2023-09-22 |
| AU2022230548A1 (en) | 2023-09-28 |
| US20240076691A1 (en) | 2024-03-07 |
| JP2024509224A (ja) | 2024-02-29 |
| IL305679A (en) | 2023-11-01 |
| CR20230429A (es) | 2024-03-08 |
| CO2023011679A2 (es) | 2024-01-15 |
| CL2023002629A1 (es) | 2024-04-01 |
| UY39659A (es) | 2022-09-30 |
| CA3212809A1 (en) | 2022-09-09 |
| CN117716038A (zh) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11654201B2 (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
| RU2577971C2 (ru) | Система для увеличения экспрессии генов и вектор, содержащий указанную систему | |
| CA3097375A1 (en) | Modified aav capsid polypeptides for treatment of muscular diseases | |
| CO2021002965A2 (es) | Moléculas de ácido nucleico y sus usos para la terapia génica no viral | |
| US10016514B2 (en) | Polynucleotides, vectors and methods for insertion and expression of transgenes | |
| RU2017142006A (ru) | Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов | |
| PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
| US20220396813A1 (en) | Recombinase compositions and methods of use | |
| WO2021128692A1 (en) | Liver-specific promoter and application thereof | |
| JP2023537625A (ja) | 新規ａａｖカプシド及びそれを含む組成物 | |
| WO2021078833A1 (en) | Chimeric polypeptides and uses thereof | |
| AR125041A1 (es) | Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix, y su uso | |
| WO2022130014A1 (en) | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein | |
| AR123826A1 (es) | Molécula polinucleotídica recombinante aislada que codifica una proteína disferlina humana, sistema de vectores virales adenoasociados (aav) duales, sistema de empaquetamiento de aav y métodos relacionados | |
| CN115176022A (zh) | 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法 | |
| AU2020411330B2 (en) | Liver-specific promoter and application thereof | |
| US20230279398A1 (en) | Treating human t-cell leukemia virus by gene editing | |
| US20230242942A1 (en) | Dual-vector system for treating hearing impairment and use thereof | |
| RU2021133872A (ru) | Модуляторы экспрессии гена открытой рамки считывания 72 хромосомы 9 и их применения | |
| WO2021078834A1 (en) | Chimeric acid-alpha glucosidase polypeptides and uses thereof | |
| AR126727A1 (es) | Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 | |
| CN117897492A (zh) | 用于肌肉和cns中的基因表达的杂合启动子 | |
| CN112236516A (zh) | 针对氧化应激的基因疗法 | |
| RU2023126231A (ru) | Варианты b4galt1 и их применение | |
| JPWO2020219726A5 (es) |